PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1756848

Lobar hypoplasia.

C Della Pona·G Rocco·A Rizzi·M Robustellini·G Rossi·B Crasti
View original source ↗Export metadata ↓

Abstract

Lung tissue developmental abnormalities are seldom reported. According to the classification of Schneider (1900), which was amended by Boyden (1955), they include pulmonary agenesis, aplasia and hypoplasia. Due to the early onset of symptoms, lung agenesis and aplasia are usually detected soon after birth. Conversely, lung or lobar hypoplasia may remain clinically silent for a long time. A single case of left lower lobe hypoplasia is reported. A recurring and unrelenting septic fever was the presenting symptom, whilst the radiological picture showed a left lower lobe consolidation. On the surgical specimen gross pathology revealed a lobar hypoplasia. At a short-term follow-up (nine months) the patient shows good overall condition, being free from further complications.

Explore related subjects

Fever of Unknown OriginHumansLungMaleMiddle AgedRespiratory Tract InfectionsTomography, X-Ray ComputedCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Della Pona, G Rocco, A Rizzi, M Robustellini, G Rossi, B Crasti. 1991. Lobar hypoplasia.. https://pubmed.ncbi.nlm.nih.gov/1756848/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

[Positron emission tomography: current use in internal medicine and future perspectives].

PURPOSE: Fluorodeoxyglucose positron emission tomography (FDG-PET) is a promising imaging technique that has already proven effective in modifying patient care in oncology. Fluorodeoxyglucose still remains the main radiopharmaceutical agent routinely used for PET imaging. A growing interest has recently lead to broaden PET research on benign disorders. The field of inflammatory or immune diseases and globally the field of internal medicine could also be impacted by FDG-PET. MAIN POINTS: Great vessels vasculitides and fever of unknown origin have both been studied by several teams and could become indications for PET. In addition, current indications now extend to paraneoplastic syndromes. It is thus possible to foresee that the clinical applications for PET will continue to expand in these patients. PERSPECTIVES AND PROJECTS: In the future, inflammatory arthritis, chronic inflammatory bowel diseases, systemic erythematous lupus, histiocytosis, or pulmonary and retroperitoneal fibrosis might benefit from PET even if, available data remains scarce to this day. Although PET will probably alter the landscape of patient management in internal medicine in the near future, additional clinical research is still needed to ascertain the exact role of PET.

Fever of Unknown Origin↗